Mangalam Drugs & Organics (NSE:MANGALAM) Other Long-Term Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
44 GF Score
Price ₹31.74
GF Value ₹61.94
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Other Long-Term Liabilities?

Mangalam Drugs & Organics NSE:MANGALAM -0.63% 44 Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:MANGALAM with a GF Score™ of 44/100 and a GF Value™ of ₹61.94 (Possible Value Trap). The stock has 4 warning signs investors should review.

Mangalam Drugs & Organics's other long-term liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Mangalam Drugs & Organics's quarterly other long-term liabilities increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹68 Mil) but then declined from Mar. 2026 (₹68 Mil) to Jun. 2026 (₹0 Mil).

Mangalam Drugs & Organics's annual other long-term liabilities declined from Mar. 2024 (₹154 Mil) to Mar. 2025 (₹141 Mil) and declined from Mar. 2025 (₹141 Mil) to Mar. 2026 (₹68 Mil).

Mangalam Drugs & Organics Other Long-Term Liabilities Related Terms

Mangalam Drugs & Organics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Other Long-Term Liabilities Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.95 145.16 153.58 140.95 67.66

Mangalam Drugs & Organics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 74.89 0.00 67.66 0.00
NSE:MANGALAM
44GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹0 Mil mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Other Long-Term Liabilities of ₹0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Other Long-Term Liabilities too high?
Mangalam Drugs & Organics' current Other Long-Term Liabilities is ₹0 Mil. Overall, Mangalam Drugs & Organics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Other Long-Term Liabilities compare to ZTS?
Mangalam Drugs & Organics' Other Long-Term Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Other Long-Term Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹61.94, compared to a current price of ₹31.74 — trading 48.8% below its estimated fair value. The current Other Long-Term Liabilities is ₹0 Mil. Mangalam Drugs & Organics' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Other Long-Term Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹31.74 is trading 48.8% below its estimated GF Value™ of ₹61.94. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Other Long-Term Liabilities: ₹0 Mil
  • GF Value™: ₹61.94 vs. price of ₹31.74 (48.8% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
44GF Score

Get the complete analysis for NSE:MANGALAM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.74
Price
₹61.94
GF Value